Abstract: Allergic rhinitis(AR) is a prevalent immune-mediated inflammatory disorder of the nasal cavity, immune-inflammatory response in the nasal mucosa as it fundamental pathological feature. Transient receptor potential vanilloid receptor 1(TRPV1) as a non-selective cation channel, upon activation, triggers the release of neurogenic inflammatory mediators such as substance P(SP), calcitonin gene-related peptide(CGRP), and vasoactive intestinal peptide(VIP), among others, these mediators collectively contribute to the modulation of neurogenic inflammation. Recent studies have demonstrated that TRPV1 and its associated neurogenic inflammatory mediators exert significant regulatory effects on AR and its pathological manifestations. This review aims to summarize the advancements in research regarding TRPV1-mediated neurogenic inflammatory mediators in AR, thereby providing a theoretical foundation for both basic research and novel drug development targeting AR.